The current Chronic Inflammatory Demyelinating Polyneuropathy Market Size was estimated at USD 1.996 billion in 2024. This substantial valuation is primarily a reflection of the high price point of immunoglobulin treatments and the long-term, continuous nature of patient care required to manage this chronic condition.

The high growth projection for the Chronic Inflammatory Demyelinating Polyneuropathy Market Size to USD 4.332 billion by 2035 indicates strong investment confidence. This growth is expected to be fueled by the successful commercialization of biologics and specialized immunotherapies that address the limitations of existing treatments and expand the therapeutic toolkit available to neurologists.